|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||194.49 - 196.76|
|52-week range||194.49 - 196.76|
|Beta (5Y monthly)||1.39|
|PE ratio (TTM)||92.62|
|Earnings date||25 Apr 2023 - 01 May 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
RESEARCH TRIANGLE PARK, N.C., March 14, 2023--In 2022, global clinical trial activity remained resilient even as the COVID-19 pandemic stretched through the year, with a 1% decline in non-COVID trial activity compared to 2021. COVID-19 trials as a percentage of total trial activity dropped from 10% to 6% of the 5,756 total trials run in 2022. Non-COVID trial activity increased by 8% between 2019 and 2022, suggesting a restoration to pre-pandemic growth rates, according to a new report, Global Tr
IQVIA Holdings Inc. ( NYSE:IQV ) shareholders might be concerned after seeing the share price drop 11% in the last...
RESEARCH TRIANGLE PARK, N.C., March 01, 2023--IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV), announced today that Ron Bruehlman, executive vice president and chief financial officer, will speak at the Barclays Global Healthcare Conference in Miami, FL on Wednesday, March 15, 2023 at 9:30 a.m. ET.